Vladimir V. Bubnov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vladimir V. Bubnov has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- K V Litovkin3 shared publications
Evgeny A. Moskalev
Functional Genome Analysis, Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany
2 shared publicationsJörg D. Hoheisel
Functional Genome Analysis, Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany
2 shared publications- Mahdi Fallah
German Cancer Research Center (DKFZ)
2 shared publications Pouria Jandaghi
Functional Genome Analysis, Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany
2 shared publications- Sandeep Kumar Botla
Karolinska Institutet, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 21 February 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (6) , 4418-4427
GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers
GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers
- 21 February 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (6) , 4418-4427
Open AccessGHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers
GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers
- Open Access
- 20 November 2013
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Biopolymers and Cell
- Vol. 29 (6) , 463-467
Impact of siRNA transfection on tumor development under experimental pathology of thyroid gland
Aim. To assess the impact of siRNA transfection on the tumor development under experimental pathology of the thyroid gland. Methods. Experiments were performed on rats weighing 180 ± 20 g, which were divided into five groups: IA and IB – animals with simulated hypo- and hyperthyroid states and transplanted Guerin’s carcinoma; IIA and IIB – animals with simulated hypo- and hyperthyroid states and transplanted Guerin’s carcinoma in combination with siRNA transfection; III – control group with transplanted Guerin’s carcinoma in combination with siRNA transfection. Orthogonal dimensions of the tumor were measured. Histological and immunohistochemical researches of tumor samples were performed. Results. It has been shown that the inhibitory effect of short interfering RNA is realized to a greater extent in the hypothyroid state, indicating an important role of thyroid hormones in the regulation of expression of genes that control the cell cycle. We discuss a possible dependence of necrobiotic processes prevalence and characteristic changes in the blood vessels on the effects of thyroid hormones on angiogenesis and proliferative processes. Conclusions. siRNA trasfection leads to inhibition of tumor growth in animals with both hypo- and hyperthyroidism, but it is more pronounced at hypothyroidism.\u
- 20 November 2013
- Published by Institute of Molecular Biology and Genetics (NAS Ukraine) in Biopolymers and Cell
- Vol. 29 (6) , 463-467
Open AccessImpact of siRNA transfection on tumor development under experimental pathology of thyroid gland
Aim. To assess the impact of siRNA transfection on the tumor development under experimental pathology of the thyroid gland. Methods. Experiments were performed on rats weighing 180 ± 20 g, which were divided into five groups: IA and IB – animals with simulated hypo- and hyperthyroid states and transplanted Guerin’s carcinoma; IIA and IIB – animals with simulated hypo- and hyperthyroid states and transplanted Guerin’s carcinoma in combination with siRNA transfection; III – control group with transplanted Guerin’s carcinoma in combination with siRNA transfection. Orthogonal dimensions of the tumor were measured. Histological and immunohistochemical researches of tumor samples were performed. Results. It has been shown that the inhibitory effect of short interfering RNA is realized to a greater extent in the hypothyroid state, indicating an important role of thyroid hormones in the regulation of expression of genes that control the cell cycle. We discuss a possible dependence of necrobiotic processes prevalence and characteristic changes in the blood vessels on the effects of thyroid hormones on angiogenesis and proliferative processes. Conclusions. siRNA trasfection leads to inhibition of tumor growth in animals with both hypo- and hyperthyroidism, but it is more pronounced at hypothyroidism.\u
- 17 August 2012
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 135 (3) , 705-713
Diagnostic values of GHSR DNA methylation pattern in breast cancer
DNA methylation patterns have been recognised as cancer-specific markers with high potential for clinical applications. We aimed at identifying methylation variations that differentiate between breast cancers and other breast tissue entities to establish a signature for diagnosis. Candidate genomic loci were analysed in 117 fresh-frozen breast specimens, which included cancer, benign and normal breast tissues from patients as well as material from healthy individuals. A cancer-specific DNA methylation signature was identified by microarray analysis in a test set of samples (n = 52, p < 2.1 × 10−4) and its performance was assessed through bisulphite pyrosequencing in an independent validation set (n = 65, p < 1.9 × 10−7). The signature is associated with SFRP2 and GHSR genes, and exhibited significant hypermethylation in cancers. Normal-appearing breast tissues from cancer patients were also methylated at these loci but to a markedly lower extent. This occurrence of methylated DNA in normal breast tissue of cancer patients is indicative of an epigenetic field defect. Concerning diagnosis, receiver operating characteristic curves and the corresponding area under the curve (AUC) analysis demonstrated a very high sensitivity and specificity of 89.3 and 100 %, respectively, for the GHSR methylation pattern (AUC >0.99). To date, this represents the DNA methylation marker of the highest sensitivity and specificity for breast cancer diagnosis. Functionally, ectopic expression of GHSR in a cell line model reduced breast cancer cell invasion without affecting cell viability upon stimulation of cells with ghrelin. Our data suggest a link between epigenetic down-regulation of GHSR and breast cancer cell invasion.
- 17 August 2012
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 135 (3) , 705-713
Diagnostic values of GHSR DNA methylation pattern in breast cancer
DNA methylation patterns have been recognised as cancer-specific markers with high potential for clinical applications. We aimed at identifying methylation variations that differentiate between breast cancers and other breast tissue entities to establish a signature for diagnosis. Candidate genomic loci were analysed in 117 fresh-frozen breast specimens, which included cancer, benign and normal breast tissues from patients as well as material from healthy individuals. A cancer-specific DNA methylation signature was identified by microarray analysis in a test set of samples (n = 52, p < 2.1 × 10−4) and its performance was assessed through bisulphite pyrosequencing in an independent validation set (n = 65, p < 1.9 × 10−7). The signature is associated with SFRP2 and GHSR genes, and exhibited significant hypermethylation in cancers. Normal-appearing breast tissues from cancer patients were also methylated at these loci but to a markedly lower extent. This occurrence of methylated DNA in normal breast tissue of cancer patients is indicative of an epigenetic field defect. Concerning diagnosis, receiver operating characteristic curves and the corresponding area under the curve (AUC) analysis demonstrated a very high sensitivity and specificity of 89.3 and 100 %, respectively, for the GHSR methylation pattern (AUC >0.99). To date, this represents the DNA methylation marker of the highest sensitivity and specificity for breast cancer diagnosis. Functionally, ectopic expression of GHSR in a cell line model reduced breast cancer cell invasion without affecting cell viability upon stimulation of cells with ghrelin. Our data suggest a link between epigenetic down-regulation of GHSR and breast cancer cell invasion.
- 15 July 2010
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 68 (1) , 151-158
Involvement of xanthine oxidase and hypoxia-inducible factor 1 in Toll-like receptor 7/8-mediated activation of caspase 1 and interleukin-1β
Inflammatory reactions to ssRNA viruses are induced by the endosomal Toll-like receptors (TLRs) 7 and 8. TLR7/8-mediated inflammatory reaction results in activation of the Nalp3 inflammasome via an unknown mechanism. Here we report for the first time that TLR7/8 mediate activation of xanthine oxidase (XOD) in an HIF-1α-dependent manner. XOD produces uric acid and reactive oxygen species, which could activate Nalp3 and therefore induce activation of caspase 1, known to convert inactive pro-IL-1β into active IL-1β. Specific inhibition of the XOD activity attenuates TLR7/8-mediated activation of caspase 1 and IL-1β release. These results were obtained using human THP-1 myeloid macrophages. The findings were verified by conducting in vivo experiments on mice.
- 15 July 2010
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 68 (1) , 151-158
Involvement of xanthine oxidase and hypoxia-inducible factor 1 in Toll-like receptor 7/8-mediated activation of caspase 1 and interleukin-1β
Inflammatory reactions to ssRNA viruses are induced by the endosomal Toll-like receptors (TLRs) 7 and 8. TLR7/8-mediated inflammatory reaction results in activation of the Nalp3 inflammasome via an unknown mechanism. Here we report for the first time that TLR7/8 mediate activation of xanthine oxidase (XOD) in an HIF-1α-dependent manner. XOD produces uric acid and reactive oxygen species, which could activate Nalp3 and therefore induce activation of caspase 1, known to convert inactive pro-IL-1β into active IL-1β. Specific inhibition of the XOD activity attenuates TLR7/8-mediated activation of caspase 1 and IL-1β release. These results were obtained using human THP-1 myeloid macrophages. The findings were verified by conducting in vivo experiments on mice.
- 1 June 2008
- Vol. 30 (2) , 106-11
Microarray study of gene expression in uterine leiomyoma.
Uterine leiomyoma is a most common benign neoplasm in women of reproductive age. It arises from the myometrial compartment of the uterus and may transform in some cases to a malignant phenotype. To identify the genes involved in pathogenesis of uterine leiomyoma. We have studied differential gene expression in matched tissue samples of leiomyoma and normal myometrium from the very same people utilizing a cDNA microarray screening method. We also compared our results with previously published microarray data to identify the overlapping gene alterations. Based on this comparison we can divide genes deregulated in our study into two groups. The first group comprises genes that to our knowledge have not been previously reported as deregulated in fibroids: CLDN1, FGF7 (KGF), HNRPM, ISOC1, MAGEC1 (CT7), MAPK12, RFC, TIE1, TNFRSF21 (DR6). The second group consists of genes identified also in previous studies: CCND1 (BCL1), CDKN1A (P21), CRABP2, FN1 and SOX4 (EVI16). In our study FN1 was the most up-regulated gene, occupying the place between the myometrium and fibroids ranging from 2.07 to 3.64, depending of the probe molecule used for detection. Newly identified genes may be regarded as potential diagnostic or prognostic markers of uterine leiomyoma and thus may be very useful as new therapeutic candidates.
- 1 June 2008
- Vol. 30 (2) , 106-11
Microarray study of gene expression in uterine leiomyoma.
Uterine leiomyoma is a most common benign neoplasm in women of reproductive age. It arises from the myometrial compartment of the uterus and may transform in some cases to a malignant phenotype. To identify the genes involved in pathogenesis of uterine leiomyoma. We have studied differential gene expression in matched tissue samples of leiomyoma and normal myometrium from the very same people utilizing a cDNA microarray screening method. We also compared our results with previously published microarray data to identify the overlapping gene alterations. Based on this comparison we can divide genes deregulated in our study into two groups. The first group comprises genes that to our knowledge have not been previously reported as deregulated in fibroids: CLDN1, FGF7 (KGF), HNRPM, ISOC1, MAGEC1 (CT7), MAPK12, RFC, TIE1, TNFRSF21 (DR6). The second group consists of genes identified also in previous studies: CCND1 (BCL1), CDKN1A (P21), CRABP2, FN1 and SOX4 (EVI16). In our study FN1 was the most up-regulated gene, occupying the place between the myometrium and fibroids ranging from 2.07 to 3.64, depending of the probe molecule used for detection. Newly identified genes may be regarded as potential diagnostic or prognostic markers of uterine leiomyoma and thus may be very useful as new therapeutic candidates.
- 1 December 2007
- Vol. 29 (4) , 295-8
Interleukin-6 -174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study.
A common G/C polymorphism at position -174 of the interleukin-6 (IL-6) gene promoter is thought to affect the expression level of this gene, thus predisposing to a variety of diseases, including tumorigenesis. To investigate the association of the -174 G/C IL-6 polymorphism with breast cancer and uterine leiomyoma in Ukrainian population. We genotyped the -174 G/C IL-6 polymorphism in a group of healthy Ukrainians by pyrosequencing and compared the results to those previously published for other Caucasian populations. The same genotyping procedure was applied to the local populations of breast cancer and uterine leiomyoma patients. The frequencies of IL-6 alleles -174G and -174C were similar to those observed in populations from Germany-Austria, the Netherlands, UK and Northern Ireland. In cancer patients as well as in the controls the two alleles occurred at an approximate ratio 1.7 : 1 in favor of the ancestral G-allele. In contrast, there was a significant increase of the C-allele frequency in the population of leiomyoma patients as compared with the controls. The -174G/C IL-6 polymorphism is not a risk factor of major importance for breast cancer in the Ukrainian population. However, there is a trend for association between the mutant C-allele and susceptibility to uterine leiomyoma.
- 1 December 2007
- Vol. 29 (4) , 295-8
Interleukin-6 -174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study.
A common G/C polymorphism at position -174 of the interleukin-6 (IL-6) gene promoter is thought to affect the expression level of this gene, thus predisposing to a variety of diseases, including tumorigenesis. To investigate the association of the -174 G/C IL-6 polymorphism with breast cancer and uterine leiomyoma in Ukrainian population. We genotyped the -174 G/C IL-6 polymorphism in a group of healthy Ukrainians by pyrosequencing and compared the results to those previously published for other Caucasian populations. The same genotyping procedure was applied to the local populations of breast cancer and uterine leiomyoma patients. The frequencies of IL-6 alleles -174G and -174C were similar to those observed in populations from Germany-Austria, the Netherlands, UK and Northern Ireland. In cancer patients as well as in the controls the two alleles occurred at an approximate ratio 1.7 : 1 in favor of the ancestral G-allele. In contrast, there was a significant increase of the C-allele frequency in the population of leiomyoma patients as compared with the controls. The -174G/C IL-6 polymorphism is not a risk factor of major importance for breast cancer in the Ukrainian population. However, there is a trend for association between the mutant C-allele and susceptibility to uterine leiomyoma.
- 1 June 2007
- Vol. 29 (2) , 152-5
Identification of new DNA markers of endometrial cancer in patients from the Ukrainian population.
To identify clinically significant molecular markers of endometrial cancer. Cancer and normal endometrial tissue samples from 20 patients of the Gynecology Clinic of Odessa State Medical University (Odessa, Ukraine) with confirmed endometrial cancer were compared for SSR and ISSR polymorphisms. Identified polymorphic fragments from anonymous genome regions situated between microsatellite repeats underwent direct DNA sequencing; analysis of their homology to sequences from human genome database has been performed. No significant variability for the microsatellite loci adjacent to the E2F1, BAX, TCF7L2, C-MYC, WNT1, FES, DCC, P27, THRA, APC, CYP19 and P53 genes was detected. Search for new molecular markers of endometrial cancer within anonymous DNA sequences located between microsatellite repeats revealed 100 bp and 174 bp polymorphic fragments. These fragments were detected correspondingly in 60% and 35% of patients. 100 bp fragment appeared to be homologous to a region within the NFKB gene, 174 bp fragment - to a sequence within the DDR1 gene. NFKB1 and DDR1 genes may be regarded as potential markers for some types of endometrial cancer. This is a first report about possible association of these genes with endometrial cancer.
- 1 June 2007
- Vol. 29 (2) , 152-5
Identification of new DNA markers of endometrial cancer in patients from the Ukrainian population.
To identify clinically significant molecular markers of endometrial cancer. Cancer and normal endometrial tissue samples from 20 patients of the Gynecology Clinic of Odessa State Medical University (Odessa, Ukraine) with confirmed endometrial cancer were compared for SSR and ISSR polymorphisms. Identified polymorphic fragments from anonymous genome regions situated between microsatellite repeats underwent direct DNA sequencing; analysis of their homology to sequences from human genome database has been performed. No significant variability for the microsatellite loci adjacent to the E2F1, BAX, TCF7L2, C-MYC, WNT1, FES, DCC, P27, THRA, APC, CYP19 and P53 genes was detected. Search for new molecular markers of endometrial cancer within anonymous DNA sequences located between microsatellite repeats revealed 100 bp and 174 bp polymorphic fragments. These fragments were detected correspondingly in 60% and 35% of patients. 100 bp fragment appeared to be homologous to a region within the NFKB gene, 174 bp fragment - to a sequence within the DDR1 gene. NFKB1 and DDR1 genes may be regarded as potential markers for some types of endometrial cancer. This is a first report about possible association of these genes with endometrial cancer.